Jazz Pharmaceuticals

JAZZ

Market cap $7.82B

Overview Fund Activity

128.93 USD

-0.61

0.47%

At close Updated Sep 18, 9:41 AM EDT

1 day

-0.47%

5 days

0.78%

1 month

9.57%

3 months

19.11%

6 months

-7.58%

Year to date

4.18%

1 year

17.67%

5 years

-9.14%

10 years

-19.42%

About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Employees: 2,800

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

736% more call options, than puts

Call options by funds: $69.8M | Put options by funds: $8.34M

10% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 11 (+1) [Q2]

3.39% more ownership

Funds ownership: 98.7% [Q1] → 102.08% (+3.39%) [Q2]

7% more repeat investments, than reductions

Existing positions increased: 188 | Existing positions reduced: 176

9% less funds holding

Funds holding: 545 [Q1] → 497 (-48) [Q2]

12% less capital invested

Capital invested by funds: $7.44B [Q1] → $6.56B (-$882M) [Q2]

42% less first-time investments, than exits

New positions opened: 58 | Existing positions closed: 100

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$151

17% upside

Avg. target

$181

41% upside

High target

$205

59% upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Goldman Sachs Madhu Kumar	$185	Buy Maintained	29 Aug 2025
Morgan Stanley Jeffrey Hung	$163	Overweight Maintained	28 Aug 2025
RBC Capital Leonid Timashev	$151	Outperform Maintained	28 Aug 2025
Truist Securities Gregory Fraser	$205	Buy Maintained	28 Aug 2025
Needham Ami Fadia	$202	Buy Reiterated	28 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about JAZZ published over the past 30 days

Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

Modeyso, the first treatment option for this ultra-rare and aggressive brain tumor, is commercially available in the United States For U.S. media and investors only DUBLIN , Sept. 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Modeyso™ (dordaviprone) is recommended by the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A single-agent treatment option for pediatric and adult patients with recurrent or progressive diffuse high-grade glioma harboring an H3 K27M mutation.

Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 9:30 AM EDT Company Participants Amal Melhem-Bertrandt Philip Johnson - Executive VP & CFO Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Thank you very much for joining us today. My name is Mohit Bansal.

Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

DUBLIN , Aug. 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2025 Wells Fargo Healthcare Conference. Company management will participate in a fireside chat on Wednesday, September 3, 2025, at 6:30 a.m.

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

Zacks Investment Research

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

DUBLIN , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host an investor webcast on Wednesday, August 27, 2025, at 4:30 p.m. EDT / 9:30 p.m.

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications For U.S. media and investors only DUBLIN and COPENHAGEN, Denmark , Aug. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Saniona (Nasdaq OMX: SANION) today announce that the companies have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator in preclinical development for epilepsy and other potential indications, designed to overcome the limitations of non-selective Kv7-targeting compounds. Jazz will lead and fund further development, regulatory submissions, and global commercialization activities.

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Zacks Investment Research

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an overall response rate in patients with progressive disease following prior therapy Company to host investor webcast on August 27, 2025 For U.S. media and investors only DUBLIN , Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial.1 Modeyso is the first and only treatment option approved by the FDA for this ultra-rare and aggressive brain tumor that affects an estimated 2,000 people in the U.S. each year, many of whom are children and young adults.2 The disease is characterized by rapid progression and historically has had no effective systemic treatment options.3 To address this urgent unmet patient need, Modeyso is expected to be commercially available in the coming weeks. "This is a major turning point in neuro-oncology," said Patrick Wen, M.D.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

US FDA approves Jazz Pharma's drug for rare brain tumor

The U.S. Food and Drug Administration said on Wednesday that it has approved Jazz Pharmaceuticals' drug to treat diffuse midline glioma, a rare and aggressive tumor, in adults and children aged one year and older.

US FDA approves Jazz Pharma's drug for rare brain tumor

Zacks Investment Research

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

See News Rankings

Charts implemented using Lightweight Charts™